ArticleMolecular and clinical oncology2026
Downregulation of MGST3 promotes colorectal cancer progression.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC), the third most common malignancy worldwide, presents significant treatment challenges due to an incomplete understanding of its molecular progression. Therefore, identifying the specific developmental mechanisms of CRC holds potential to improve diagnosis, treatment and prognosis. In the present study, RNA-sequencing analysis of samples from patients with an early-stage tumor, advanced carcinoma or adenoma was conducted with the aim of uncovering differentially expressed genes. At the same time, gene knockdown and tumor-related phenotype verification were conducted using a normal colon epithelial cell line. Subsequently, a group of genes related to the target gene was analyzed using The Cancer Genome Atlas (TCGA) database and the differences in colon tumor mutation burden, immune infiltration, epithelial-mesenchymal transition (EMT) and ferroptosis were observed between samples with high and low expression of the gene group. Microsomal glutathione S-transferase 3 (MGST3) was identified as a crucial tumor-suppressive gene in colon cancer pathogenesis. Functional studies demonstrated that MGST3 knockdown in normal human colonic epithelial cells activated glutathione metabolic pathways and induced tumorigenic transformation, characterized by accelerated proliferation and suppression of EMT. TCGA database analysis revealed distinct phenotypes associated with low MGST3 expression, including elevated tumor mutational burden, attenuated EMT processes, diminished immune cell infiltration and enhanced ferroptosis. These findings establish MGST3 as a potential novel regulator of colon carcinogenesis, with its downregulation creating a tumor microenvironment conducive to ferroptosis while simultaneously suppressing EMT and immune responses. The present study not only elucidates previously unrecognized mechanisms driving colon cancer progression but also identifies MGST3-related pathways as promising therapeutic targets for intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.